219 articles with NovoCure Ltd.
Novocure (NASDAQ: NVCR) will participate in the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 9, 2019, in San Francisco.
Novocure and the AACR Announce Four Inaugural Research Grants to Promote and Support Innovative Research on Tumor Treating Fields
The grants represent a joint effort to promote and support innovative research on Tumor Treating Fields.
Sub-Group Analysis of Novocure’s EF-14 Phase 3 Pivotal Trial in Newly Diagnosed Glioblastoma Published in Journal of Neuro-Oncology Demonstrating More Time on Optune® Predicted Increased Survival
Novocure (NASDAQ:NVCR) announced today that the results of a retrospective post-hoc sub-group analysis of its EF-14 phase 3 pivotal trial in newly diagnosed glioblastoma (GBM) have been published in the Journal of Neuro-Oncology.
Novocure and Zai Lab Awarded Deal of the Year at 5th Annual BioCentury China Healthcare Summit in Shanghai, China
Novocure announced today that Novocure and Zai Lab have received the Deal of the Year Award from BayHelix at a ceremony during the 5th annual BioCentury China Healthcare Summit in Shanghai, China
Novocure Announces More than 70 Presentations on Tumor Treating Fields at 23rd Annual Meeting of the Society for Neuro-Oncology
Presentations span 21 research areas with five oral presentations
Novocure announced today that it will host an investor event with Zai Lab on Nov. 14, 2018, in Shanghai, China. William Doyle, Novocure’s Executive Chairman, Dr. Samantha Du, Zai Lab’s CEO, and Tao Fu, Zai Lab’s President and Chief Operating Officer, will review the strategic collaboration for Tumor Treating Fields in Greater China and address questions from the audience.
Quarterly net revenues of $64.8 million, representing 29 percent growth versus the third quarter 2017 and 5 percent growth versus the second quarter 2018
Higher Delivered Dose of Tumor Treating Fields to Tumor Bed Associated with Improved Overall Survival in Newly Diagnosed Glioblastoma
Post-hoc analysis of EF-14 phase 3 pivotal trial demonstrated that power loss density and electric field intensity were associated with improved overall survival, independent of compliance
Pancreatology Publishes Results of the PANOVA Phase 2 Pilot Trial in Advanced Pancreatic Cancer Suggesting Improved Survival of Patients Treated with Tumor Treating Fields
The Tumor Treating Fields plus gemcitabine and nab-paclitaxel patient cohort showed progression free and one-year survivals that were more than double those of the gemcitabine and nab-paclitaxel-treated historical control
Novocure Announces that the Medicare DME MACs Have Accepted the Local Coverage Determination Reconsideration Request for Optune®
Per Centers for Medicare & Medicaid Services (CMS) and Medicare policy, the two DME MACs will issue a single joint policy applicable in all DME regions.
Highlights include a data analysis of EF-14 that demonstrated an increased dose of Tumor Treating Fields to the tumor bed improved overall survival in GBM patients as well as safety data from a surveillance study
Novocure management will host a conference call and webcast to discuss its financial results for the three and nine months ended September 30, 2018, at 8 a.m. EDT on Thursday, October 25, 2018.
Data from STELLAR Registration Trial of Tumor Treating Fields in Mesothelioma to be Presented at the IASLC 19th World Conference on Lung Cancer
Mesothelioma patients who received Tumor Treating Fields with pemetrexed and cisplatin or carboplatin experienced median overall survival of 18.2 months compared to 12.1 months in historical control with no increase in systemic toxicity
Novocure and Zai Lab Announce Strategic Collaboration with a License Agreement for Tumor Treating Fields in Greater China
Zai Lab granted license to commercialize oncology platform technology Tumor Treating Fields, including the brand name Optune®, in China, Hong Kong, Macau and Taiwan
Novocure and US Oncology Research Announce Collaboration on PANOVA-3 Trial for Patients with Advanced Pancreatic Cancer
US Oncology Research will open 10 clinical trial sites, enrolling patients in Novocure’s PANOVA-3 trial to test the efficacy of Tumor Treating Fields combined with nab-paclitaxel and gemcitabine in patients with unresectable locally advanced pancreatic cancer
Novocure announced that it will participate in two upcoming investor conferences.
Jeryl Hilleman, Chief Financial Officer of Intersect ENT, elected to board of directors
Gynecologic Oncology Publishes Results of the INNOVATE Phase 2 Pilot Study Demonstrating Combination of Tumor Treating Fields with Paclitaxel May Improve Survival of Patients with Recurrent Ovarian Cancer
Progression free survival of patients treated with Tumor Treating Fields plus weekly paclitaxel was more than double that of weekly paclitaxel-treated historical controls.
Quarterly net revenues of $61.5 million, representing 60 percent growth versus the second quarter 2017 and 18 percent growth versus the first quarter 2018
The volume of Tumor Treating Fields presentations marks a record number of abstracts for Novocure at this conference